First sale of TexRAD in South Korea

RNS Number : 3371L

Feedback PLC

27 April 2015

 

27 April 2015

Feedback plc

("Feedback" or the "Company")

First sale of TexRAD in South Korea

Feedback plc (AIM: FDBK), the medical imaging software company, announces the first sale for research purposes of Feedback's TexRAD texture analysis software in South Korea. As part of the new PET-CT scanner installed by Siemens at Seoul National University Bundang Hospital, (SNUBH), TexRAD software was purchased for use by the Nuclear Medicine department at SNUBH to undertake research studies in cancer and other diseases. Uniteko Co.,Ltd are the Siemens PETNET Korea Co., Ltd ("Siemens") authorised distributor who facilitated the purchase and installation process of TexRAD research software at SNUBH on behalf of Siemens.

SNUBH is one of the specialty branches of the Seoul National University Hospital system. It is South Korea's national medical research hospital dedicated to the study and treatment of geriatric diseases. When SNUBH opened in 2003, it was the first fully digital, paperless hospital in the Asia-Pacific region. It is now the digital cornerstone of the South Korean national healthcare system and is a world leader in the use of data to inform clinical decision-making in the diagnosis and management of individual patients.

Dr. Ho-Young Lee, Assistant Professor in the Department of Nuclear Medicine, Seoul National University, College of Medicine, SNUBH  commented, "We are very excited with the prospects of using the TexRAD imaging research software platform in conjunction with the new  PET-CT  scanner being installed at our institution, further reinforcing our vision and reputation of being early adopters of new technologies, particularly in the fascinating area of quantitative imaging and its applications in cancer care."

TexRAD research software will extract key heterogeneity information via a novel quantitative texture analysis approach from SNUBH's cancer imaging datasets. TexRAD has already established itself as a leading, innovative texture analysis software product, currently employed as a research tool in a number of prestigious imaging centres and university hospitals in the UK, EU, and USA. Similarly it is envisaged that TexRAD will assist in enhancing the research output in cancer imaging at SNUBH and identify potential clinical applications and impact on care management of cancer patients in the future."

Dr. Balaji Ganeshan, Chief Scientist and New Business Officer at the Company's subsidiaries TexRAD Ltd and Cambridge Computed Imaging Ltd, commented, "We are delighted to receive this order - a first on several fronts: Firstly, working with a leading original equipment manufacturer (OEM) on this sale, bundling TexRAD research software with the OEM offering and lastly but not least, entry into the Korean market - particularly the prestigious Seoul National University Bundang Hospital who are keen to undertake further exciting research in cancer imaging. This will open up new avenues and opportunities for Feedback in establishing itself and fulfilling its vision as an innovative multi-modality medical imaging software company."

For further information contact:

Feedback plc	Tel: [phone]
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser and Joint Broker)	Tel: [phone]
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd (Joint Broker)	Tel: [phone]
Lucy Williams / Duncan Vasey

Notes to editors:

TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'.TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

 

END

 

 

DISZMGZDLVNGKZM